Contact
Please use this form to send email to PR contact of this press release:
AVM Biotechnology Announces Full Enrollment of First Cohort of Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients
TO:
Jena Dalpez
AVM Biotechnology
+ 12069069922